Exploring and evaluating treatment methods and clinical trials for Diffuse Large B-cell Lymphoma (DLBCL)
New Hope for Refractory DLBCL: Cutting-edge Clinical Trials
Diffuse Large B-cell Lymphoma (DLBCL) is a subtype of non-Hodgkin's lymphoma, and for those living with refractory or relapsed DLBCL, the outlook has traditionally been negative. However, recent advancements in targeted therapies are offering new hope.
One such treatment is R-CHOP, a modified version of CHOP that includes the addition of the monoclonal antibody drug rituximab. R-CHOP targets cancer cells with a particular marker (CD20). Although the overall outlook for people living with refractory or relapsed DLBCL is still challenging, with a low overall response rate to treatment, studies have shown that R-CHOP can improve outcomes.
Targeted therapies, including CAR T-cell therapy, have shown to increase overall survival rates and response to treatment in people living with DLBCL. CAR T-cell therapy is a type of targeted immunotherapy used to treat relapsed or refractory DLBCL, involving harvesting T cells, altering them in a lab, and reintroducing them to combat cancer cells.
Clinical trials are ongoing for new treatments for DLBCL, including studies examining the effectiveness of CAR T-cell therapies. One such trial is testing if adding brentuximab vedotin improves outcomes versus lenalidomide plus rituximab alone in relapsed/refractory patients. Other trials are evaluating new CAR-T therapies, such as Zamtocabtagene Autoleucel (MB-CART2019.1), at institutions like Mayo Clinic and UCSD.
Standard salvage chemo-immunotherapy options before stem cell transplant remain important, such as R-GDP, R-DHAP, and R-ICE regimens, often followed by autologous stem cell transplant if the lymphoma responds well.
For patients relapsed or progressing after CAR-T therapy, no standard exists yet, but a spectrum of treatments including allogeneic stem cell transplant, BTK inhibitors, bispecific antibodies, checkpoint inhibitors, chemo(immuno)therapy, lenalidomide or polatuzumab-based regimens, and novel agents like tafasitamab or loncastuximab are under evaluation. Ongoing trials are critical for advancing management.
In summary, cutting-edge clinical trials are exploring combinations of antibody-drug conjugates, novel targeted agents, and advanced cell therapies like CAR-T, alongside established chemo-immunotherapy and transplant strategies, offering multiple avenues for patients with relapsed or refractory DLBCL. Those living with refractory or relapsed DLBCL may want to discuss clinical trial options with an oncologist, as participating in studies can help researchers find new and improved options.
[1] ClinicalTrials.gov Identifier: NCT04173249 [2] ClinicalTrials.gov Identifier: NCT03735856 [3] ClinicalTrials.gov Identifier: NCT04338887 [4] ClinicalTrials.gov Identifier: NCT03852684 [5] ClinicalTrials.gov Identifier: NCT04008697
- The new hope for refractory Diffuse Large B-cell Lymphoma (DLBCL) lies in cutting-edge clinical trials, with one such trial exploring the addition of brentuximab vedotin to improve outcomes, as identified by NCT04173249.
- The advancements in the field of oncology, such as targeted therapies, have shown significant improvements in blood cancers like DLBCL, including increasing overall survival rates with CAR T-cell therapy, which is being tested in trials like NCT03735856.
- In the realm of medical-conditions like cancer, various therapies and treatments are under evaluation for refractory or relapsed DLBCL, such as Zamtocabtagene Autoleucel (MB-CART2019.1), currently being tested in trials like NCT04338887.
- For patients with refractory or relapsed DLBCL who have progressed after CAR-T therapy, new treatment options are under investigation, which include a variety of health-and-wellness enhancing approaches like allogeneic stem cell transplant, BTK inhibitors, bispecific antibodies, checkpoint inhibitors, and novel agents like tafasitamab, as per NCT03852684 and NCT04008697.
){kind=link}